Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Lucas Walz"'
Autor:
Lucas Walz, Avi J. Cohen, Andre P. Rebaza, James Vanchieri, Martin D. Slade, Charles S. Dela Cruz, Lokesh Sharma
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed. Janus kinase-inhibitors
Externí odkaz:
https://doaj.org/article/8aa441c37fc24cea9f30c2bcac259f9d
Autor:
Kaveh Khoshnood, Jude Alawa, Samir Al-Ali, Lucas Walz, Eleanor Wiles, Nikhil Harle, Mohamed Abdullahi Awale, Deqo Mohamed
Publikováno v:
BMJ Open, Vol 11, Iss 6 (2021)
Objectives This study examined knowledge and perceptions of COVID-19, prevalence of pre-existing conditions and access to essential resources among residents of internally displaced person (IDP) camps in Somalia, where overcrowded settlements with we
Externí odkaz:
https://doaj.org/article/d12c4b2cab3443aead4de4b15c1e622e
Autor:
Jude Alawa, Lucas Walz, Samir Al-Ali, Nikhil Harle, Eleanor Wiles, Mohamed Abdullahi Awale, Deqo Mohamed, Kaveh Khoshnood
Publikováno v:
PLoS ONE, Vol 16, Iss 11, p e0259981 (2021)
BackgroundSomalia is considered severely underprepared to contain an outbreak of COVID-19, with critical shortages in healthcare personnel and treatment resources. In limited-resource settings such as Somalia, providing healthcare workers with adequa
Externí odkaz:
https://doaj.org/article/2a2d9acc38f44c0bb47f0c6a78b94173
Publikováno v:
Developmental Medicine & Child Neurology.
Autor:
Lucas Walz, Deqo Mohamed, Adam Haibah, Nikhil Harle, Samir Al-Al, Ayan Aden Moussa, Jude Alawa, Mohamed Abdullahi Awale, Kaveh Khoshnood
Publikováno v:
ecancermedicalscience. 16
Somali women face exceptionally high mortality and incidence rates from both breast cancer (BC) and cervical cancer (CC). They experience the highest age-standardised BC mortality rate in Africa and an age-standardised BC incidence rate of 41.7 per 1
Publikováno v:
The Journal of Pediatrics. 255:220-223.e1
Publikováno v:
Multiple Sclerosis and Related Disorders. 68:104219
The median survival time of newly-diagnosed MS patients without severe disabilities is approximately 30-35 years. The prognosis after the onset of severe disability has not been reported. Based on Harding et al.'s 2018 study of the Southeast Wales MS
Autor:
Eleanor Wiles, Mohamed Abdullahi Awale, Samir Al-Ali, Nikhil Harle, Jude Alawa, Lucas Walz, Kaveh Khoshnood, Deqo Mohamed
Publikováno v:
BMJ Open, Vol 11, Iss 6 (2021)
BMJ Open
BMJ Open
ObjectivesThis study examined knowledge and perceptions of COVID-19, prevalence of pre-existing conditions and access to essential resources among residents of internally displaced person (IDP) camps in Somalia, where overcrowded settlements with wea
Autor:
Avi J. Cohen, Lucas Walz, Charles S. Dela Cruz, James Vanchieri, Lokesh Sharma, Andre P Rebaza, Martin D. Slade
Publikováno v:
Research Square
article-version (status) pre
article-version (number) 1
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-10 (2021)
article-version (status) pre
article-version (number) 1
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-10 (2021)
Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed. Janus kinase-inhibitors and Type
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4d0e589ffa4499e6075fec20fd8801
https://doi.org/10.21203/rs.3.rs-64782/v1
https://doi.org/10.21203/rs.3.rs-64782/v1
Autor:
James Vanchieri, Andre P Rebaza, Lucas Walz, Avi J. Cohen, Martin D. Slade, Lokesh Sharma, Charles S. Dela Cruz
Publikováno v:
BMC Infectious Diseases
medRxiv
article-version (status) pre
article-version (number) 1
medRxiv
article-version (status) pre
article-version (number) 1
BackgroundNovel coronavirus (SARS-CoV-2) has infected over 17 million. Novel therapies are urgently needed. Janus-kinase (JAK) inhibitors and Type I interferons have emerged as potential antiviral candidates for COVID-19 patients for their proven eff